Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

B7$4

04/05/10 8:08 AM

Post #3

"SMMX News" Accelrys, Inc. and Symyx Technologies, Inc. Announce Merger Creates a New Leader in Scientific Informatics Software

http://www.marketwire.com/press-release/Accelrys-Inc-and-Symyx-Technologies-Inc-Announce-Merger-NASDAQ-ACCL-1142357.htm

SAN DIEGO, CA and SANTA CLARA, CA--(Marketwire - April 5, 2010) - Accelrys, Inc. (NASDAQ: ACCL) and Symyx Technologies, Inc. (NASDAQ: SMMX) today announced that they have signed a merger agreement that will establish a new leader in scientific informatics software.

The merger, structured as a tax-free, all-stock merger of equals, was approved by both companies' Boards of Directors. On a combined basis, Accelrys and Symyx have a pre-announcement market capitalization of approximately $335 million, cash reserves of approximately $150 million (net of transaction costs), and no debt. Under the terms of the agreement, Symyx shareholders will receive 0.7802 shares of Accelrys common stock for each share of Symyx. Following the completion of the merger, Accelrys and Symyx shareholders will each own approximately 50 percent of the combined company. After a period of initial integration, full year net cost synergy savings are expected to be in the range of $10 million - $15 million. Additionally, the transaction is expected to be materially accretive to Non GAAP Earnings per Share.

The merger is expected to be completed by the end of June 2010, subject to customary closing conditions, shareholder and regulatory approvals.

Max Carnecchia, chief executive officer of Accelrys, will serve as chief executive officer of the combined company. Isy Goldwasser, chief executive officer of Symyx Technologies, will serve a transitional role in the combined company. The company will be headquartered in San Diego, California.

"Scientific R&D organizations are challenged by the need to increase productivity and performance while grappling with budget pressures, restructuring, changes in scientific processes, and globally dispersed operations," said Max Carnecchia, chief executive officer of Accelrys. "These forces are creating profound changes in the processes of scientific discovery and the way R&D teams interact. New software solutions are urgently required to address these fundamental changes, and the merger of Accelrys and Symyx creates a new, leading-force in the industry to address this situation."

"The merger of Accelrys and Symyx creates a differentiated company that is uniquely qualified to advance the state of the scientific informatics software industry," said Isy Goldwasser, chief executive officer of Symyx Technologies. "No other company combines our deep domain knowledge in chemistry, biology and materials science, enterprise software capabilities (in scientific data management, decision support and analytics), professional expert services, and a broad choice of partners. This powerful and synergistic combination with Accelrys allows us to meet the changing needs of our customers by delivering more agile, flexible and open scientific R&D environments through adaptive end-to-end workflow solutions."

The combined company will have more than 1,350 customers, including 29 of the top 30 biopharmaceutical companies, all five top chemical companies, all five top aerospace companies, three of the five top consumer packaged goods companies, a number of top US Federal Government Agencies, as well as many top academic institutions.

buhg1b

03/14/08 7:13 PM

Post #2

Overvalued

Stock is overpriced imho.

buhg1b

03/11/08 10:29 AM

Post #1

Symyx Joins Microsoft BioIT Alliance
Monday March 3, 8:30 am ET

SANTA CLARA, CA--(MARKET WIRE)--Mar 3, 2008 -- Symyx Technologies, Inc. (NasdaqGS:SMMX - News) announced today that it has joined the Microsoft BioIT Alliance, a cross-industry group working to enhance collaboration among life sciences organizations to accelerate the pace of drug discovery and development.

"Comprehensive data integration -- making complex life sciences data easier to manage and easier to share -- requires new levels of cooperation between software companies," said Timothy Campbell, President of Symyx Software. "Symyx is delighted to be part of Microsoft's BioIT Alliance initiative. As a technology leader in integrated laboratory workflow systems, R&D software and research services in the life sciences and related industries, we look forward to working closely with Microsoft's partner community to explore new and better ways of capturing, managing and sharing R&D data. Through improved collaboration, multidisciplinary R&D organizations can solve critical life sciences problems more quickly and bring new products to market with less risk."

Rudy Potenzone, Worldwide Industry Technology Strategist for Pharmaceuticals and BioIT Alliance Coordinator, said: "We are very pleased to welcome Symyx to the BioIT Alliance. Their broad experience and contribution to this community will help the Alliance and its members as we look to expand our activities in the coming months."

The BioIT Alliance is designed to enable collaboration among organizations in the life sciences field in order to shorten the time between discovery of new biological data and the application of that knowledge to human health. Symyx will work with other alliance members to consider innovative ways to address the challenges of data integration, collaboration, and knowledge management and use Microsoft technology to reduce costs, streamline research and market products more effectively.

About Symyx

Symyx Technologies, Inc. is the scientific R&D integration partner to companies in the life sciences, chemicals, energy, electronics and consumer products industries. With scientific R&D under tremendous economic and technical pressure, we help companies reduce R&D risk and enhance R&D productivity to help them bring more and better products to market quickly and cost-effectively. Our integrated technology platform combines Symyx Software (electronic laboratory notebooks, content, laboratory logistics and analysis), Symyx Tools (software-driven integrated workflows) and Symyx Research (collaborative research and directed services) to support the entire R&D process. In October 2007, Symyx acquired MDL Information Systems, Inc., a leading provider of innovative informatics software, databases and services that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Information about Symyx, including reports and other information filed by Symyx with the Securities and Exchange Commission, is available at www.symyx.com.

About BioIT Alliance

Formed in 2006, the BioIT Alliance is a cross-industry group working to integrate science and technology in order to accelerate the pace of drug discovery and realize the potential of personalized medicine. Founding members include Accelrys Software Inc., Affymetrix, Inc., Agilent Technologies Inc., Amylin Pharmaceuticals, Inc., Applied Biosystems, The BioTeam Inc., Digipede Technologies LLC, Discovery Biosciences Corporation, Geospiza Inc., Hewlett-Packard Development Company, L.P., Illumina Inc., InterKnowlogy, Microsoft Corporation, Sun Microsystems Inc., The Scripps Research Institute, VizX Labs LLC and other key companies in the pharmaceutical, biotech, hardware and software industries. Additional information about the BioIT Alliance can be found on the BioIT Alliance Web site at http://www.bioitalliance.org

About Microsoft

Founded in 1975, Microsoft (NasdaqGS:MSFT - News) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential. For more information, please visit www.microsoft.com

Symyx is a registered trademark of Symyx Technologies, Inc. Microsoft is a registered trademark of the Microsoft Corporation in the United States and other countries. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

Contact:

For more information:
Teresa J. Thuruthiyil
Vice President, Investor and Public Relations
Symyx Technologies, Inc.
(408) 773-4075
Email Contact

Source: Symyx Technologies, Inc.

http://biz.yahoo.com/iw/080303/0369233.html

Symyx Technologies Incorporated (SMMX)

Followers	0	Posters	2
Posts (Today)	0	Posts (Total)	3
Created	03/10/08	Type	Free
Moderators

Moderator's Disclaimer - This board is for Symyx discussion purposes only and in no way a recommendation to invest or not in this stock. Any investment decisions should be based on your own due diligence and decision. You are solely responsible for your choices to buy or sell. This is a disclaimer and in no way holds the moderators legally liable for your investments.

BUYER BEWARE!

Symyx Technologies, Inc. engages in the development and application of research technologies and research software for the chemicals, energy, life science, consumer product, and other industries. It offers research services on behalf of collaborative partners. The company also provides Symyx Tools, which include high-throughput reactors, screening systems, robots, and other analytical equipment. These instruments are integrated with Symyx Software, which facilitates the process of designing, executing, and evaluating research and development. Symyx Technologies licenses automation and data mining applications, as well as ELN software. Its Symyx Software enhances experiment design, laboratory automation, data capture, data analysis and visualization, and data communication in high-throughput and traditional research environments. The company also provides associated support, maintenance, and consulting services. In addition, it offers selective access to its intellectual property through patent licensing, materials licensing, technology licensing, and original equipment manufacturer software licensing. The company, through its 38% interest in Visyx Technologies, Inc., provides development services and licenses for specific applications to intellectual property associated with the company's sensor technology. It operates in North America, Europe, and Japan. Symyx Technologies was founded in 1994 and is headquartered in Santa Clara, California. 3100 Central Expressway Santa Clara, CA 95051 Phone: 408-764-2000 Fax: 408-748-0745 www.symyx.com Management Mr. Steven D. Goldby, 67 Exec. Chairman Mr. Isy Goldwasser, 37 Chief Exec. Officer, Pres Dr. Peter G. Schultz Ph.D., 51 Co-Founder and Advisor Dr. W. Henry Weinberg Ph.D., 63 Chief Scientific Officer and Exec. VP Ms. Jeryl L. Hilleman, 50 Advisor Estimated Market Cap 211,189,617 as of Mar 7, 2008 Outstanding Shares 33,469,036 as of Oct 31, 2007 Number of Share Holders of Record 110 as of Feb 27, 2007 Transfer Agent Wells Fargo Shareholder Services (Minneapolis, MN), A Division of Wells Fargo Bank 161 N. Concord Exchange P.O. Box 738 South St. Paul, MN 55101 CIK - 0001095330 Chart{/b] 2007 Commentary Isy Goldwasser, Symyx chief executive officer, stated, "Outsourcing, globalization, regulation and changing product economics are challenging R&D organizations in our target markets to deliver results more efficiently and quickly than ever before. In 2007, Symyx significantly strengthened its product portfolios, sales and support organizations and management team to help our customers in these markets successfully address these challenges. "With the important changes of 2007 in place, including our fourth quarter acquisition of MDL Information Systems, our focus for 2008 is on execution, driving better results and continued improvements in operating discipline in Symyx Software, Symyx Tools and Symyx Research," concluded Mr. Goldwasser. "During the fourth quarter, we turned in a solid quarter for our historical Symyx business lines, realized more MDL revenue than forecasted, and generated stronger software consulting revenue than expected," added Rex S. Jackson, Symyx chief financial officer. "Earnings benefited from higher revenues, lower than expected restructuring expenses, lower than expected amortization of acquisition-related intangibles, favorable product mix and continuing expense management. We were also pleased with our cash management during the quarter, exiting with $45.5 million in cash, cash equivalents and available-for-sale securities." Fourth Quarter 2007 Financial Results For the fourth quarter of 2007, Symyx reported revenue of $48.5 million. Fourth quarter revenue by type was $18.4 million in service revenue primarily from research collaborations and software consulting services, $18.2 million in product revenue from Symyx Tools sales, $11.9 million in license fees, content revenue and royalties... Symyx reiterated its full year 2008 revenue range of $165-175 million. Symyx' revenue outlook is supported by ongoing commitments to R&D investments by leading technology customers such as Borealis, The Dow Chemical Company, Eli Lilly & Company and ExxonMobil. Recently, Symyx executed extensions of existing agreements with both Dow and ExxonMobil. Symyx currently forecasts revenue from each of Dow and ExxonMobil of approximately $25-$27 million in 2008, for a total of $50-$54 million and in line with previous guidance. For 2009, Symyx is currently forecasting $21-$25 million from Dow and approximately $16-$19 million from ExxonMobil. The Company expects full year 2008 net loss per share to be in the range of $(0.34)-$(0.28). This estimate does not include the approximately $0.13 per share that would be attributable to the $7 million of MDL's 2008 deferred revenue that the Company cannot recognize under GAAP, but includes amortization expenses of approximately $13 million, or approximately $0.23 per share, for certain intangibles related to the Company's acquisitions, and approximately $5.3 million, or $0.10 per share, in non-cash stock-based compensation expenses. For the first quarter of 2008, Symyx forecasts revenue of $34-$38 million, and a GAAP loss per share of ($0.24)-($0.18). Symyx' first quarter range does not include the approximately $0.07 per share that would be attributable to the approximately $4 million of deferred MDL revenue that the Company cannot recognize under GAAP in the first quarter, and includes approximately $3.2 million, or $0.06 per share of amortization of acquisition-related intangibles, and approximately $1.5 million, or $0.03 per share, in non-cash stock-based compensation expenses..." Source: www.sec.gov [b]Photo